News

The FDA accepted EntreMed's application upon review of data from in vitro studies in glioma cell lines that demonstrate the antiproliferative activity of Panzem (2-methoxyestradiol, or 2ME2). Additionally,

CoTherix has also acquired exclusive rights to develop and commercialize oral formulations of Fasudil for the treatment of stable angina in the same territories. Under the terms of

The results of the trial of Nymox's lead drug candidate for the treatment of benign prostatic hyperplasia (BPH), were reported during a recent review of safety data from

Jerusalem-based Intec will develop and manufacture the drug using the Accordion Pill technology, while California-based Impax will conduct clinical trials and commercialize the product. The financial terms of

Following the submission of its investigational new drug (IND) application to the Food and Drug Administration (FDA), the New Jersey-based company says it is now preparing for a

Under the terms of the agreement, the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes for Health (NIH), will fund and conduct

The purpose of the transaction is to explore Durolane and other products for the management of osteoarthritis (OA) in joints and to explore other orthopedic uses and diseases.

The closure follows the US company’s acquisition of Agis. Since the takeover, Perrigo has been pursuing opportunities to integrate both businesses and streamline production. The global healthcare supplier

Spherics has developed advanced oral systems based on the application of proprietary bioadhesive polymers to oral dosage forms. These broadly enabling technologies have potential to expand the therapeutic